Overview

The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes

Status:
Recruiting
Trial end date:
2024-10-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to prove that the group treated with D745 in combination added that the reduction of HbA1c superior to placebo treated group added in combination.
Phase:
Phase 3
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical